■这项观察性研究评估了boswellia,姜黄,和红藻提取物在膝骨关节炎(KOA)患者中的应用。鉴于对骨关节炎以患者为中心的护理的兴趣与日俱增,通过患者报告的预后指标(PROMs)进行疗效评估:患者可接受症状量表(PASS),最小临床重要性改善(MCII)患者总体变化印象(PGIC),和Lequesne算法功能指数(LAFI)。患者还完成了关于疼痛质量的17个项目的列表。
单侧或双侧KOA疼痛的患者必须每天服用1-4粒含有乳香的膳食补充剂,姜黄,和红藻提取物90天。患者在第0天(基线)完成PROM,10、20、30、60和/或90。
■共有118名患者[女性:69.5%;年龄:62.9(9.5)岁,平均(SD)]纳入研究,并服用至少一粒胶囊。平均(SD)随访时间为100.7(54.9)天。第90天疼痛缓解最大:64.5%的患者为应答者(PASS阳性);68.8%和58.4%的MCII和PGIC评分表明积极效果(评分≥3)或整体改善(评分≥5);73.3%(基线为47.5%)轻度/中度残疾(LAFI评分<8);55.2%的疼痛强度(VAS)有意义的降低(-30%),35.1%(基线为59.2%)服用镇痛药作为补充治疗。第一次PASS改变的中位时间为34天。疼痛强度(VAS),以及两个疼痛特征(即,“刺痛”和“广泛疼痛”),是与第30天无应答相关的独立因素。根据疼痛特征分离出四组反应者,一个集群表现出更高的响应率。
■这项初步研究的结果表明,boswellia,姜黄,和测试的红藻提取物可以改善KOA患者。除了这些结果,这项研究表明,PROM和特定疼痛定性描述符对于准确评估疼痛状态下的膳食补充剂方法的重要性.
UNASSIGNED: This observational
study evaluated a combination of boswellia, turmeric, and red algae extracts in patients with knee osteoarthritis (KOA). Given the growing interest in patient-centered care in osteoarthritis, effects were assessed by an arsenal of patient-reported outcome measures (PROMs): Patient Acceptable Symptom Scale (PASS), Minimal Clinically Important Improvement (MCII), Patient Global Impression of Change (PGIC), and Lequesne algofunctional index (LAFI). Patients also completed a list of 17 items on pain quality.
UNASSIGNED: Patients with painful unilateral or bilateral KOA had to take 1-4 capsules per day of a dietary supplement containing boswellia, turmeric, and red algae extracts for 90 days. Patients completed PROMs on Days 0 (baseline), 10, 20, 30, 60, and/or 90.
UNASSIGNED: A total of 118 patients [female: 69.5%; age: 62.9 (9.5) years, mean (SD)] were included in the
study and took at least one capsule. Mean (SD) follow-up duration was 100.7 (54.9) days. Pain relief was maximal on Day 90: 64.5% of patients were responders (positive PASS); 68.8% and 58.4% had MCII and PGIC scores indicating positive effect (score ≥3) or global improvement (score ≥5); 73.3% (versus 47.5% at baseline) were mildly/moderately disabled (LAFI score <8); 55.2% had meaningful decrease (-30%) in pain intensity (VAS), 35.1% (versus 59.2% at baseline) took analgesics as supplementary treatment. Median time to the first PASS change was 34 days. Pain intensity (VAS), as well as two pain characteristics (ie, \"Stabbing pain\" and \"Widespread pain\"), were independent factors associated with non-response on Day 30. Four clusters of responders were isolated according to pain characteristics, with one cluster exhibiting a higher responder rate.
UNASSIGNED: The results of this preliminary
study suggest that the combination of boswellia, turmeric, and red algae extracts tested could improve KOA patients. Beyond these results, this
study showed the importance of PROMs and specific pain qualitative descriptors for the accurate evaluation of dietary supplement approaches in painful conditions.